2026-04-13T03:10:57Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1870242025-12-05T12:39:40Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc González-Juanatey, J. R. author Anguita Sánchez, Manuel author Bayés Genís, Antoni author Comín Colet, Josep author García Quintana, Antonio author Recio Mayoral, Alejandro author Zamorano Gómez, José Luis author Cepeda Rodrigo, José María author Manzano, L. author 2022-06-27T08:45:46Z 2022-06-27T08:45:46Z 2022-02-01 2022-06-23T13:08:22Z Despite currently available treatments, risk of death and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) remains high. The pathophysiology of HFrEF includes neurohormonal activation characterized by stimulation of deleterious pathways (i.e., sympathetic nervous and renin-angiotensin-aldosterone systems) and suppression of pro-tective pathways such as nitric oxide-dependent pathways. Inhibition or stimulation of some, but not all, of these pathways is insufficient. In HFrEF, there is reduced nitric oxide, soluble guanylate cyclase, and cGMP activity, leading to deleterious effects in the myocardial, vascu-lar, and renal systems. Vericiguat is able to stimulate the activity of this protective pathway. The VICTORIA study demonstrated that the addition of vericiguat to optimal medical treatment in patients with HFrEF and recent decompensation significantly reduced the incidence of the primary endpoint, a composite of cardiovascular death or HF hospitalization, with a number needed to treat of 24 patients and excellent tolerability. Insuficiència cardíaca Farmacologia cardiovascular Heart failure Cardiovascular pharmacology Vericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica